Comparing two drug combinations for multiple myeloma after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma.
- You have already had a stem cell transplant after receiving at least 4 different induction medicines.
- Your most recent transplant was within the last 6-7 months.
- Tests after your transplant show a small number of myeloma cells still in your bone marrow (called minimal residual disease).
- You are 18 years or older and generally able to care for yourself (Karnofsky score of 50% or more).
- Your liver and kidney function are within acceptable levels for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this approach can better control the disease.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.